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Purpose: Muscle-derived stem cells (MDSCs) harvested from skeletal muscles have the 
advantage of providing easier access and do not pose the immunogenic risks of embry-
onic stem cells. We investigated the effect of intracavernosal transplantation of MDSCs 
on erectile function in rats with bilateral cavernous nerve injury.
Materials and Methods: Adult male white rats underwent experimentation in 3 groups: 
group I, sham operation; group II, bilateral cavernous nerve injury; group III, bilateral 
cavernous nerve injury with MDSC injection. MDSCs were harvested from the femoral 
muscle of rats and were then injected into the cavernosum. Survival of MDSCs and 
measurement of erectile function was studied after 4 weeks. We checked the intra-
cavernosal pressure (ICP) and obtained penile tissue. The expression of cyclic guano-
sine monophosphate (cGMP) was analyzed.
Results: Four weeks after transplantation, PKH-26-labeled MDSCs were identified in 
the cavernosal tissues of group III. Peak ICP and the drop rate of group II were 52±8.7
mmHg and 34±6.5 mmHg/min, respectively, whereas peak ICP and the drop rate of 
group III were 97±15.6 mmHg and 17±4.9 mmHg/min, respectively, showing that erec-
tile function improved after MDSC transplantation (p＜0.05). The expression of cGMP 
was significantly lower in group II (21.9±5.8 fmol/well) than in group I and group III 
(70.2±10.3 and 58.9±10.5 fmol/well, respectively). 
Conclusions: In a cavernous nerve injury rat model, intracavernosal transplantation 
of MDSCs showed acceptable survival of MDSCs as well as improvement of erectile 
function.
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INTRODUCTION
Erectile dysfunction is a common complication after radi-
cal prostatectomy. With detailed understanding of the 
anatomy of the cavernous nerves [1], nerve-sparing proce-
dures have been developed [2] and applied to carefully se-
lected patients. Nevertheless, considerable numbers of pa-
tients who undergo radical prostatectomy become impotent. 
In one study, among men who were potent at baseline, the 
proportion who were impotent 18 or more months after sur-
gery was 65.6% of men undergoing non-nerve-sparing pro-
cedures, 58.6% of men undergoing unilateral nerve-spar-
ing procedures, and 56.0% of men undergoing bilateral 
nerve-sparing procedures [3]. Recovery of erectile dysfunc-
tion is slow, usually taking months to years, and even if the 
nerve-sparing procedure is done by experienced hands, one 
third of patients need the aid of medications such as phos-
phodiesterase inhibitors [4].Korean J Urol 2011;52:359-363
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　Cell transplantation and tissue engineering is an emerg-
ing field of science. In the field of urology, attempts have 
been made to engineer urological tissues, including the 
urethra [5], bladder [6,7], and ureter [8]. These studies used 
autologous organ-specific cells to regenerate correspon-
ding organs, but the use of such cells required a lot of time 
and material for cell proliferation; also, such cells could not 
be used in malignant conditions [9]. For these reasons, stem 
cells have emerged as the current trend in the study of cell 
transplantation and tissue engineering during the past 
decade. Muscle-derived stem cells (MDSCs) are adult stem 
cells located in muscles that are known to not only pro-
liferate into muscle cells but also differentiate into various 
other tissues such as bone, cartilage, and fat [10]. Previously, 
umbilical cord blood mesenchymal stem cells were used in 
a rat model of cavernous nerve injury and showed improved 
erectile function [11]. In this study, we transplanted MDSCs 
in a rat model of cavernous nerve injury to study the effect 
on erectile function and also looked at the survival rate of 
MDSCs through immunohistochemical staining.
MATERIALS AND METHODS
1. Experimental animals
The Institutional Animal Care and Use Committee of the 
School of Medicine, the Catholic University of Korea, ap-
proved the experimental protocol. Sixteen-week-old adult 
white rats (Saemtaco Bio Inc., Osan, Korea) weighing about 
300 to 350 g were used. Experimental groups were divided 
into 3: a control group (n=5, group I), a bilateral cavernous 
nerve injury group (n=5, group II), and a bilateral cav-
ernous nerve injury group with MDSC injection (1x10
6 cells 
in 20 μl; n=5, group III).
2. Purification and proliferation of MDSCs
MDSCs were harvested from the femoral muscles of white 
rats by use of a modified preplate technique as previously 
described [12,13]. First, muscle tissue was extracted from 
the femoral muscle of the white rat and was minced into 
a coarse slurry with razor blades. Cells were enzymatically 
dissociated by the addition of collagenase-type XI 0.2% for 
1 hour at 37.1
oC, dispase (grade II 240 unit) for 45 minutes, 
and trypsin 0.1% for 30 minutes. The dissociated cells were 
preplated on a collagen-coated flask for 1 hour and this 
flask was termed pp1. The nonadhering cells were then 
transferred to another collagen-coated flask for 2 hours to 
obtain pp2 and this procedure was repeated at 24-hour in-
tervals until pp4. The pp4 population was used for this 
experiment. The proliferation medium was Dulbecco’s 
modified Eagle’s medium with 10% fetal bovine serum, 
10% horse serum, 0.5% chick embryo extract, and 1% pen-
icillin/streptomycin. Proliferation was done for 4 days. All 
culture media and other supplies were purchased from 
Gibco Laboratories (Grand Island, NY, USA).
3. Cavernous nerve transection and transplantation of 
MDSCs
Tiletamine 0.2 ml was administered intraperitoneally for 
anesthesia. A low-midline abdominal incision was made, 
exposing the bladder and prostate. The pelvic ganglion was 
identified at the area lateral to the prostate on both sides. 
From the pelvic ganglion, cavernous nerves were identified 
to travel post-laterally into the corpus cavernosum. Group 
I rats were closed without nerve injury. In group II rats, the 
cavernous nerves were transected 2 to 3 mm distal to the 
pelvic ganglion and the wound was sutured. In group III 
rats, the cavernous nerves were transected and MDSCs 
(1x10
6 cells in 20 μl) labeled with PKH-26 fluorescent cell 
linker (Sigma, St. Louis, MO, USA) were injected into the 
corpus cavernosum and the wound was then sutured.
4. Measurement of peak intracavernosal pressure and drop 
rate
After 4 weeks, peak intracavernosal pressure (ICP) and the 
drop rate were measured for all rats. Tiletamine 0.2 ml was 
administered intraperitoneally for anesthesia. A low-mid-
line abdominal incision was made and the pelvic ganglion 
and cavernous nerve were exposed on both sides. The penis 
was also opened and the corpus cavernosum was exposed. 
A 23 G needle connected to a polyethylene tube was in-
serted into the corpus cavernosum to measure peak ICP 
and the drop rate. Papaverine (5 mg/kg) was injected into 
the corpus cavernosum to induce erection. 
5. Histology
After measurement of peak ICP and the drop rate, the pe-
nises were removed and the rats were sacrificed with intra-
venous sodium pentobarbital (100 mg/kg). The tissue 
specimens were fixed in 4% paraformaldehyde solution at 
4
oC for one day. The next day, the specimens were serially 
transferred into 10%, 20%, and 30% sucrose that was dis-
solved in 0.1 M phosphate buffer (PB), and at each stage, 
they were left to sink down completely. They were then em-
bedded in optimal cutting temperature (OCT) compound 
(Tissue-Tek, Miles Laboratory, Elkhart, IN, USA) in liquid 
nitrogen at −80
oC and sectioned at 10 μm on a cryostat 
(Microm, Walldorf, Germany). Sections were mounted on 
gelatin-coated slides and the slides were stained for hema-
toxylin and eosin. To identify PKH-26-labeled MDSCs, 
DAPI staining was done to group III and the cells were ob-
served under a fluorescent microscope.
6. Analysis of cyclic guanosine monophosphate
Measurement of the cyclic guanosine monophosphate 
(cGMP) level was performed by the use of a commercially 
available radioimmunoassay kit, the cGMP [
125I] assay kit 
(Amersham International, Amersham, UK). The princi-
ples of the current experiment were to induce competitive 
bonding between 
125I-labeled cGMP, which is present at a 
certain amount in the cells, and intracellular cGMP, to 
measure the amount of isotopes of 
125I-labeled cGMP, and 
thereby to quantify the level of cGMP that is present in the Korean J Urol 2011;52:359-363
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FIG. 1. Measurement of erectile function by Papaverine injection.
Peak intracavernous pressure (ICP) was higher in group III than
in group II. Also, the drop rate was lower in group III than in group
II. 
a: p＜0.05.
FIG. 2. H&E staining and DAPI staining of group III at week 4. (A) H&E staining. (B) DAPI staining. PKH-26 labeled muscle-derived
stem cells (MDSCs) were identified in DAPI staining of the cavernosum of group III rats. Red spots: PKH-26.
FIG. 3.  cGMP expression of group III was higher than that of group
II. 
a: p＜0.05.
sample. Following the preliminary experiment, the level 
of cGMP was lower in the cells and tissue forming the cor-
pus cavernosum. An analysis was therefore performed by 
using an acetylation assay. Dried cytoplasmic extracts 
were dissolved by using assay buffer contained in a kit, to 
which acetylation reagent, antiserum, and [
125I]cGMP were 
added in a sequential manner. Following this, the reaction 
was performed in compliance with the kit protocol. 
Eventually, with the use of a gamma scintillation counter, 
the radioactivity (cpm/min) of each tube was measured. 
The level of cGMP of each sample was calculated by use of 
a standard curve.
7. Statistical analysis
All data are presented as means±standard deviations, and 
p-values＜0.05 are reported as significant. Comparisons 
between groups were performed by using Sigmastat for 
Windows (Systat Inc., Chicago, IL, USA). The Mann-Whitney 
test was used to compare results.
RESULTS
1. Change in erectile function
At 4 weeks, after papaverine injection to induce erection, 
the peak ICP of group I (control group) was 120±12.8 mmHg, 
that of group II (bilateral cavernous nerve injury group) 
was 52±8.7 mmHg, and that of group III [bilateral caver-
nous nerve injury group with MDSCs (1x10
6 cells in 20 ml) 
injection] was 97±15.6 mmHg. The drop rate of group I was 
10±4.1 mmHg/min, that of group II was 34±6.5 mmHg/min, 
and that of group III was 17±4.9 mmHg/min. The peak ICP 
and drop rate were significantly higher in group III than 
in group II (p＜0.05) (Fig. 1).
2. Survival of MDSCs
PHK-26 labeled MDSCs were identified by DAPI staining 
of the cavernosum of group III rats (Fig. 2).
3. Expression of cGMP
The expression of cGMP was significantly lower in group 
II (21.9±5.8 fmol/well) than in group I and group III (70.2± 
10.3 and 58.9±10.5 fmol/well, respectively) (Fig. 3).Korean J Urol 2011;52:359-363
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DISCUSSION
Radical prostatectomy is the mainstay of treatment for lo-
calized prostate cancer. The number of prostatectomies 
performed in Korea is increasing as a result of prostate-spe-
cific antigen (PSA) screening and a younger age at diagnosis 
of prostate cancer [14]. Advances in surgical techniques 
and scientific technology have led to the advent of laparo-
scopic or robotic radical prostatectomy, but despite these 
developments, erectile dysfunction is still a major compli-
cation after radical prostatectomy and it compromises the 
quality of life of many patients undergoing this procedure 
[15,16]. The primary cause of erectile dysfunction after rad-
ical prostatectomy is injury to the cavernous nerves. The 
injury leads to a decrease in elastic and smooth muscle fi-
bers and a progressive increase in collagen fibers [17], re-
sulting in fibrosis of the corpus cavernosum. Nerve-sparing 
procedures have been proven to be beneficial to sexual func-
tion after radical prostatectomy [18-20], but not all pa-
tients become potent and many patients depend on phos-
phodiesterase-5 inhibitors for satisfactory erection [4]. 
　In this study, MDSCs were injected into a rat model of 
transected cavernous nerves to investigate the effect on 
erectile function after cavernous nerve injury. MDSCs are 
adult stem cells found in muscle tissues. They are free from 
the ethical problems frequently encountered in the use of 
embryonic stem cells [21], adequate amounts are easily ob-
tained from autologous muscle biopsies in a short period 
of time, and they pose lower immunogenic and carcinogenic 
risks than do embryonic stem cells. These qualities make 
MDSCs a good material for recent studies involving cell 
transplantation and tissue engineering. 
　In this study, 4 weeks after injecting MDSCs into the cor-
pus cavernosum of bilateral cavernous nerve injury rats, 
we observed a stable survival rate of MDSCs by immuno-
staining. In the functional study, the group with bilateral 
cavernous nerve injury with MDSCs injection showed im-
proved erectile function, as peak ICP was significantly 
higher and the drop rate was lower compared with the bi-
lateral cavernous nerve injury group. Also, the increased 
cGMP expression of group III suggested that MDSCs pro-
tected the penile nerve or muscle from atrophy after cav-
ernous nerve transection. It is postulated that the MDSCs 
converted into muscle cells or neuronal cells, thereby re-
versing or preventing the fibrotic effect of the cavernous 
nerve transection seen in the bilateral cavernous nerve in-
jury group. It is these muscle cells that are thought to be 
involved in improving the erectile function. In a similar 
study, Kim et al injected skeletal-muscle derived cells 
(MDCs) into the corpora cavernosa of bilateral cavernous 
nerve injury rats [22]. Maximal ICP was significantly high-
er in the MDC injection group than in the sham injection 
group. This study further demonstrated nerve fiber re-
generation in the MDC injection group by staining for neu-
ronal marker. The investigators postulated that either the 
MDCs protected the penile nerve from atrophy after cav-
ernous nerve transection or the MDCs differentiated into 
a neuronal phenotype.
　Growth factors may also have a role in improving erectile 
function after MDSC injection. There are several reports 
of improved erectile function after growth factor therapy. 
Chen et al reported an erectile recovery effect of brain-de-
rived neurotrophic factor and vascular endothelial growth 
factor in a rat model of bilateral cavernous nerve injury, 
and Fandel et al reported similar results with intracaver-
nosal growth differentiation factor-5 [23,24]. These types 
of growth factors are thought to improve erectile function 
by regenerating injured nerve fibers. Stem cell injection 
may facilitate the activities of these growth factors. 
Bochinski et al showed improved erectile function in a rat 
model of cavernosal nerve injury after intracavernosally 
injecting embryonic stem cells that had differentiated 
along the neural cell line [25]. One of the mechanisms they 
postulated was that embryonic stem cells acted by produc-
ing growth factors.
　One of the drawbacks of this study, as in other studies 
using MDSCs, is the need for a longer period of observation 
and ways to prolong the functional effect of MDSCs. Nolazco 
et al compared the stimulatory effect of MDSCs at week 2 
and week 4 and showed that erectile function was higher 
at week 2, suggesting that new research is warranted to im-
prove the survival of MDSCs and prolong the salutary func-
tional effects for at least 3 to 6 months [26]. This means that 
a stable marker to detect donor cells for a long period would 
be required, rather than the short-lived fluorescent mark-
ers currently being used. Another drawback is that we need 
further study of the results of the differentiated cells from 
MDSCs in corpus cavernosum, even though we demon-
strated improvement in erectile function.
　Future studies in stem cell therapy would involve combi-
nation with other treatment modalities. Currently, phos-
phodiesterase-5 inhibitors are one of the main medical 
treatments of erectile dysfunction after radical prostatec-
tomy. Combining stem cell therapy with medical therapy 
could produce a synergistic effect and warrants further 
study. In addition, combination with gene therapy is al-
ready producing promising results. Bivalacqua et al dem-
onstrated improved age-related erectile dysfunction with 
the use of mesenchymal stem cells in which gene expression 
was modified by endothelial nitric oxide synthase [27]. 
Other applications of gene transfer in stem cell therapy 
may include transcription of growth factors for nerve re-
generation or modifying the differentiation capacity of stem 
cells to the experimenters’ desire. 
CONCLUSIONS
MDSCs can improve erectile function in a cavernous nerve 
injury rat model. Erectile dysfunction resulting from radi-
cal prostatectomy may be treated with intracavernosal in-
jection of MDSCs.
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